Advanced Cancer Therapeutics Secures Exclusive License to Second Anti-Cancer Therapeutic from the University of Louisville's Brown Cancer Center.LOUISVILLE, Ky. -- Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an exclusive license to develop and market 4-IPP and its related compounds, discovered by scientists at the University of Louisville's James Graham Brown For the cricketer, see . James Graham Brown (August 18 1881 — March 20 1969) was a businessman and real estate developer best known as the builder of the Brown Hotel in Louisville, Kentucky and for his philanthropy. Cancer Center (Brown Cancer Center). Brown Cancer Center researchers Dr. Robert Mitchell and Dr. John Trent discovered that 4-IPP, a novel small molecule compound, exhibits anti-tumor activity by blocking tumor-specific angiogenesis, and thus far has demonstrated a favorable safety profile in laboratory studies. As a macrophage migration inhibitory factor Macrophage migration inhibiting factor (MIF) is an inflammatory mediator associated with Rheumatoid Arthritis (RA) severity. (MIF (1) (Maker Interchange Format) An alternate file format for a FrameMaker document. A MIF file is ASCII text, which can be created in another program and imported into FrameMaker. ), this chemokine chemokine /che·mo·kine/ (ke´mo-kin) any of a group of low molecular weight cytokines identified on the basis of their ability to induce chemotaxis or chemokinesis in leukocytes (or in particular populations of leukocytes) in inflammation. promotes multiple pro-angiogenic growth factors (VEGF VEGF vascular endothelial growth factor. and IL-8) and contributes to tumor cell division, metastases Metastasis (plural, metastases) A tumor growth or deposit that has spread via lymph or blood to an area of the body remote from the primary tumor. Mentioned in: Malignant Melanoma and tumor vascularization vascularization /vas·cu·lar·iza·tion/ (vas?ku-ler-i-za´shun) 1. the process of becoming vascular. 2. angiogenesis. 3. the surgically induced development of vessels in a tissue. (i.e., angiogenesis). The University of Louisville See also
1. ^ [1] 2. ^ [2] URL accessed on June 8 2006 3. researchers have shown in the laboratory that 4-IPP could serve as front-line therapy against bulk tumors and reduce the risk of recurrence of primary tumors or eventual metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases 1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to . In addition, while initially targeted for development in oncology, 4-IPP has subsequently been evaluated for its potential to address various unmet medical needs in autoimmune related diseases such as Rheumatoid Arthritis, Lupus and Multiple Sclerosis. "Unlike most new biotechnology companies, ACT is unique in that we have a rich portfolio of potential breakthrough anti-cancer products from which to select through our innovative business arrangement with the University of Louisville's Brown Cancer Center," said Randall Riggs, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of ACT. "We are very excited to license this small molecule compound, 4-IPP, and its related compounds that could have utility in both oncology and various autoimmune diseases." About Advanced Cancer Therapeutics (ACT): ACT is a for-profit private company dedicated to advancing novel therapeutics for the prevention and treatment of cancer. ACT has successfully established a unique and innovative business model with the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center) whereby ACT is able to obtain exclusive worldwide licenses to novel cancer therapeutics discovered at Brown Cancer Center under preset business terms. ACT then fast-tracks these discoveries, including the selection process for partnership, commercialization and manufacture, to the pharmaceutical industry, and ultimately to the patients who need them. Led by Dr. Don Miller, the Brown Cancer Center employs over fifty leading scientists focused on the discovery and advancement of breakthrough cancer therapeutics for patients suffering from cancer. For more information, please visit www.advancedcancertherapeutics.com. About James Graham Brown Cancer Center The James Graham Brown Cancer Center is a key component of the University of Louisville's Health Sciences Center and UofL Health Care. As the region's leading academic, research, and teaching medical center, our patients benefit from the latest medical advances, often long before they become available in non-teaching settings. The Brown Cancer Center is affiliated with the Kentucky Cancer Program and the National Cancer Institute. It is the only cancer center in the region to use a unified approach to cancer care, with multidisciplinary teams of physicians working together to guide patients through diagnosis, treatment and recovery. For more information, visit our website www.browncancercenter.org. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion